Roche Diagnostics Operations, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Thomas Dieterle

Dirk Block

Ursula-Henrike Wienhues-Thelen

Christian Zaugg

Hans-Peter Brunner

Andre Ziegler

Johann Karl

Edelgard Anna Kaiser

Julian Braz

Cheryl Mitchell

Johan Ubby

Sandra Sanders-van Wijk

James Januzzi

Martin Hund

Roberto Latini

Serge Masson

Vinzent Rolny

Olav Lapaire

Hanspeter Brunner

Edelgard Kaiser

Sandra Sanders-Van Wijk

Methods for identifying a patient who is eligible for an intensification of heart failure therapy are disclosed. Furthermore, methods for optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy are disclosed. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described methods.

Biomarkers for risk assessment and treatment monitoring in heart failure patients guided by natriuretic peptides

The present invention is directed to a method for predicting the risk of a female subject to develop postpartum HELLP syndrome, postpartum preeclampsia, or postpartum eclampsia. The method is based on the determination of the levels of i) sFlt-1 and PlGF, or ii) Endoglin and PlGF in a first sample obtained from said subject before delivery of baby, and a second sample of from said subject obtained after delivery of baby. Moreover, encompassed by the invention are devices and kits for carrying out the method of the present invention.

Ratios of sFlt-1 to P1GF or endoglin to P1GF as biomarkers for preeclampsia related adverse outcomes after birth

The present disclosure is directed to a method of identifying a patient having heart failure as likely to respond to a therapy with a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein the patient has heart failure and undergoes a therapy with a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

Marker for statin treatment stratification in heart failure

Presented is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also described are kits and devices adapted to carry out the method.

IGFBP7 for diagnosing diastolic dysfunction

The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for optimizing B type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.

Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.

Biomarkers for risk prediction of mortality

Disclosed herein is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Also disclosed is a method of monitoring diastolic function in a patient suffering from heart failure, and kits and devices for performing the method.

The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.

Growing community of inventors

Freiburg, Germany

Thomas Dieterle